ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.M./

PTO/SB/08a (05-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10678723
Filing Date	2003-10-02
First Named Inventor	Eduardo Marban
Art Unit	1632
Examiner Name	MONTANARI, DAVID A
Attorney Docket Number	001107.00459

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	7122307		2006-10-17	Rosen et al.	
	2	6776987		2004-08-17	Edelberg et al.	
	3	6309375		2001-10-30	Glines et al.	
	4	6207422		2001-03-27	Brown et al.	
	5	6086582		2000-07-11	Altman et al.	
	6	5944710		1999-08-31	Dev et al.	
	7	5836905		1998-11-17	Lemelson et al.	
	8	5662585		1997-09-02	Willis et al.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.M./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10678723
	Filing Date	2003-10-02
	First Named Inventor	Eduardo Marban
	Art Unit	1632
	Examiner Name	MONTANARI, DAVID A
	Attorney Docket Number	001107.00459

	9	5163950		1992-11-17	Pinchuck et al.	

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20070042347		2007-02-22	Rosen et al.	
	2	20050074850		2005-04-07	Nadler et al.	
	3	20040254134		2004-12-16	Marban et al.	
	4	20040204376		2004-10-14	Marban et al.	
	5	20030195470		2003-10-16	Ponzi	
	6	20020187949		2002-12-12	Rosen et al.	
	7	20020188212		2002-12-12	Rosen et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.M./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10678723
Filing Date	2003-10-02
First Named Inventor	Eduardo Marban
Art Unit	1632
Examiner Name	MONTANARI, DAVID A
Attorney Docket Number	001107.00459

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] ¡	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1	99/32615	WO		1999-07-01	Kandel et al.		☐
	2	99/23880	WO		1990-05-20	Marban		☐
	3	00/18903	WO		2000-04-06	Marban et al.		☐
	4	00/38518	WO		2000-07-06	Leiden et al.		☐
	5	00/41731	WO		2000-07-20	Levy et al.		☐
	6	02/33111	WO		2002-04-25	Feld et al.		☐
	7	96/28537	WO		1996-09-19	Keating et al.		☐
	8	02/19966	WO		2002-03-14	Donahue et al.		☐

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add]

NON-PATENT LITERATURE DOCUMENTS [Remove]

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.M./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10678723
	Filing Date	2003-10-02
	First Named Inventor	Eduardo Marban
	Art Unit	1632
	Examiner Name	MONTANARI, DAVID A
	Attorney Docket Number	001107.00459

	1	Accili et al., "From Funny Current To HCN Channels: 20 Years Of Excitation" (2002) News Physiol. Sci. 17:32-37	☐
	2	Akhter SA et al., "Restoration Of B-Adrenergic Signaling In Failing Cardiac Ventricular Myocytes Via Adenoviral-Mediated Gene Transfer" (1997) PNAS 94:12100-12105	☐
	3	Bannister et al, "Conserved Extracellular Cysteine Residues In The Inwardly Rectifying Potassium Channel Kir2.3 Are Required For Function But Not Expression In The Membrane" (1999) FEBS Letters 485(3):393-99	☐
	4	Bauer A et al., "Inhibitory G Protein Expression Provides Physiologically Relevant Heart Rate Control In Persistent Atrial Fibrillation" (2004) Circulation 110:3115-3120	☐
	5	Brown, "Regulation Of Heartbeat By G Protein-Coupled Ion Channels" (1990) Am J. Phys. 259(6):H1621-1628	☐
	6	Campbell et al., "Therapeutic Drug Monitoring: Antiarrhythmic Drug" (1998) Br J Clin. Pharmacol. 46:307-319	☐
	7	CHEN et al., "Lack Of Muscarinic Regulation Of Ca2+ Channels In Gi2alpha Gene Knockout Mouse Hearts" (2001) Am. J. Physiol 280: H1989-H1995	☐
	8	Chiang CE et al., "The Long QT-Syndrome: Genetic Basis And Clinical Implications" (2000) J. Amer. Coll. Cardiol. 36 (1):1-12	☐
	9	Cho et al., "Creation Of A Biological Pacemaker By Cell Fusion" (2007) Circ. Res. 100 (8):1112-1115	☐
	10	Donahue JK, "Gene Therapy For Cardiac Arrhythmias"(2004) Ann. NY Acad. Sci., 1015: 332-337	☐
	11	Donahue JK et al., "Focal Modification Of Electrical Conduction In The Heart By Viral Gene Transfer" (2000) Nat. Med. 6(2): 1395-1398.	☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.M./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10678723
	Filing Date	2003-10-02
	First Named Inventor	Eduardo Marban
	Art Unit	1632
	Examiner Name	MONTANARI, DAVID A
	Attorney Docket Number	001107.00459

	12	Donahue JK et al., "Gene Therapy For Cardiac Arrhythmias" (2005) Trends Cardiovasc. Med. 15:219-224	☐
	13	Donahue JK et al., "Gene Transfer Techniques For Cardiac Arrhythmias" (2004) Ann. Med. 36(supp 1): 98-105	☐
	14	Donahue JK et al., "Ultrarapid, Highly Efficient Viral Gene Transfer To The Heart" (1997) PNAS 94:4664-4668	☐
	15	Donahue, JK et al. "Acceleration Or Widespread Adenoviral Gene Transfer To Intact Rabbit Hearts By Coronary Perfusion With Low Calcium And Serotonin" (1998) Gene Therapy 5:630-634	☐
	16	DuBrow et al., "Comparison Of Cardiac Refractory Periods In Children And Adults" (1975) Circulation 51:485-491	☐
	17	Edelberg JM, "Enhancement For Murine Cardiac Chronotropy By The Molecular Transfer Of The Human Bets2 Adrenergic Receptor cDNA" (1998) JCI 101:337-343	☐
	18	Ennis et al., "Dual Gene Therapy With SERCA1 And Kir2.1 Abbreviates Excitation Without Suppressing Contractility" (2002) JCI 109(3) 393-400	☐
	19	Er et al., "Dominant-Negative Suppression Of HCN Channels Markedly Reduces The Native Pacemaker Current (It) And Undermines Spontaneous Beating Of Neonatal Cardiomyocytes" (2003) Circulation 107:485-489	☐
	20	Fink et al., "Dominant-Negative Chimeras Provide Evidence For Homo And Heteromultimeric Assembly Of Inward Rectifier K+ Channels Proteins Via Their N-Terminal End" (1996) FEBS Letters 378(1) 64-68	☐
	21	French BA et al., "Direct In Vivo Gene Transfer Into Porcine Myocardium With Replication-Deficient Adenoviral Vectors" (1994) Circulation 90(5):2414-2424	☐
	22	Glenn CM et al., "Gene Therapy To Develop A Genetically Engineered Cardiac Pacemaker," (2003) J. Cardiocvasc. Nurs. 18:330-336	☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.M./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10678723
	Filing Date	2003-10-02
	First Named Inventor	Eduardo Marban
	Art Unit	1632
	Examiner Name	MONTANARI, DAVID A
	Attorney Docket Number	001107.00459

	23	Gros DB et al., "Connexins In Mammalian Heart Function" (1996) Bioessays 18(9):719-730	☐
	24	Hadcock, JR et al., "Cross-Regulation Between G-Protein-Mediated Pathways" (1990) JBC 265(25): 14784-14790	☐
	25	Hajjar RJ et al., "Prospects for Gene Therapy for Heart Failure" (2000) Circ. Res. 86(6) 616-621	☐
	26	Hasenfuss, G., "Animal Models Of Human Cardiovascular Disease, Heart Failure, And Hypertrophy" (1998) Cardiovascular Research 39:60-76.	☐
	27	Homo Sapiens Hyperpolarization Activated Cyclic Nucleotide-Gated Potassium Channel (HCN1) mRNA complete coding sequence, Database EMBL [online], EMBL: AF488549	☐
	28	Hoppe et al., "Distinct Gene-Specific Mechanisms Of Arrhythmia Revealed By Cardiac Gene Transfer Of Two Long-QT Disease Genes HERG And KCNE1" (2001) PNAS USA 98(9): 5335-5340	☐
	29	Hoppe et al., "Adenovirus-Mediated Inducible Gene Expression In Vivo By A Hybrid Ecdysone Receptor" (2000) Mol. Ther. 1(2):159-164	☐
	30	Hoppe et al., "Molecular Dissection Of Cardiac Repolarization By In Vivo Kv4.3 Gene Transfer" (2000) JCI 105 (8):1077-1084	☐
	31	Hoppe, UC et al., "Manipulation Of Cellular Excitability By Cell Fusion: Effects Of Rapid Introduction Of Transient Outward K+ Current On The Guinea Pig Action Potential" (1999) Circ. Res. 84(8):964-972	☐
	32	Johns DC et al., "Suppression Of Neuronal And Cardiac Transient Outward Currents By Viral Gene Transfer Of Dominant-Negative Kv4.2 Constructs" (1997) JBC 272(50): 34598-31603	☐
	33	Johns et al. "Adenovirus-Mediated Expression Of A Voltage-Gated Potassium Channel In Vitro (Rat Cardiac Myocytes) And In Vivo (Rat Liver). A Novel Strategy For Modifying Excitability" (1995) JCI 96:1152-1158	☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.M./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number	10678723
Filing Date	2003-10-02
First Named Inventor	Eduardo Marban
Art Unit	1632
Examiner Name	MONTANARI, DAVID A
Attorney Docket Number	001107.00459

	34	Kashiwakura, Y. et al., "Gene Transfer Of A Synthetic Pacemaker Channel Into The Heart: A Novel Strategy For Biological Pacing" (2006) Circulation, Vol. 114 (16):1682-1686	☐
	35	Kass-Eiser et al., "Quantitative Determination Of Adenovirus-Mediated Gene Delivery To Rat Cardiac Myocytes In Vitro And In Vivo" (1993) PNAS 90:11498-11502	☐
	36	Kickuchi K et al., "Targeted Modification Of Atrial Electrophysiology By Homogenous Transmural Atrial Gene Transfer" (2005) Circulation 111: 264-270.	☐
	37	Lalli MJ et al., "Sarcoplasmic Reticulum Ca-ATPase (SERCA) Ia Structurally Substitutes For SERCA 2a In The Cardiac Sarcoplasmic Reticulum And Increases Cardiac Ca2+ Handling Capacity" (2001) 89:160-167	☐
	38	Lawrence JH et al., "Prospects For Genetic Manipulation Of Cardiac Excitability" (1995) Adv. In Exper. Med. And Biol. 382:41-48	☐
	39	Murata et al., "Creation Of A Genetic Calcium Channel Blocker By Targeted GEM Gene Transfer In The Heart" (2004) Circ Res 95:398-405	☐
	40	Lerman, BB et al., "Mechanism Of Repetitive Monomorphic Ventricular Tachycardia" (1995) Circulation 92:421-429	☐
	41	Li et al., "Evidence For Two Components Of Delayed Rectifier K" Current In Human Ventricular Myocytes" (1996) Circulation Research 78:689-696	☐
	42	Lopatin AN et al., "Inward Rectification And Cardiac Excitability" (2002) Biologicheskie Membrany 19(1):57-65	☐
	43	Lu et al., "Density And Kinetics Of Ikr And Iks In Guinea Pig And Rabbit Ventricular Myocytes Explain Different Efficacy Of Iks Blockade At High Heart Rate In Guinea Pig And Rabbit: Implications For Arrhythmogenesis In Humans" (2001) Circulation 104:951-956	☐
	44	Marban E et al., "Biological Pacemakers As A Therapy For Cardiac Arrhythmias" (2008) Curr. Opinion in Cardiol. 23 (1):46-54	☐

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.M./

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10678723
	Filing Date	2003-10-02
	First Named Inventor	Eduardo Marban
	Art Unit	1632
	Examiner Name	MONTANARI, DAVID A
	Attorney Docket Number	001107.00459

	45	Marban E., "Circulation Research Impact Factor Sets New Record" (2001) Circ. Res. 89:101	☐
	46	Marban, E et al., "Creation Of A Biological Pacemaker By Gene- Or Cell-Based Approaches" (2007) Med. Bio. Eng. Comput. 45:133-144	☐
	47	Mazhari R et al., "Molecular Interactions Between Two Long-QT Syndrome Gene Products, HERG And KCNE2, Rationalized By In Vitro And In Silico Analysis" (2001) Circ. Res. 89:33-38	☐
	48	Muhlhauser J et al., "Safety And Efficacy Of In Vivo Gene Transfer Into The Porcine Heart With Replication-Deficient, Recombinant Adenovirus Vectors" (1996) Gene Therapy 3:145-153	☐
	49	Mullins, FM et al., "Functional Interaction Between Extracellular Sodium, Potassium And Inactivation Gating In HERG Channels" (2004) J Physiol., V. 558(3):729-744	☐
	50	Nakamura et al., "Inhibition Of Rat Ventricular IK1 With Antisense Oligonucleotides Targeted To Kir2.1 mRNA" (1998) Am. J. Phys. 274(3)(2):H892-H900	☐

If you wish to add additional non-patent literature document citation information please click the Add button [Add]

EXAMINER SIGNATURE

Examiner Signature	/David Montanari/	Date Considered	03/04/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.